keyword
https://read.qxmd.com/read/38435208/a-retrospective-public-health-assessment-and-management-in-terms-of-the-social-and-clinical-risk-factors-of-respiratory-syncytial-virus-infection-in-northern-canada
#1
JOURNAL ARTICLE
Sana Sharif Sheikh, Hina Sharif, Nadia Sharif
Background The predominant source of respiratory infections in Northern Canada stems from RSV, leading to potentially life-threatening lower respiratory tract infections in children below the age of 2. Typically, RSV begins to appear in November or December and persists until April or May. Synagis® (Palivizumab), a monoclonal antibody, is employed to mitigate or reduce the effects of RSV. Past research indicated a reduction in hospitalizations with the use of Synagis®. Aim The aim is to estimate the cost-benefit analysis by comparing the health services cost with Synagis® program cost...
February 2024: Curēus
https://read.qxmd.com/read/38032456/approaches-to-the-prevention-and-treatment-of-respiratory-syncytial-virus-infection-in-children-rationale-and-progress-to-date
#2
JOURNAL ARTICLE
Charl Verwey, Ziyaad Dangor, Shabir A Madhi
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that include vaccines and long-acting, high-potency monoclonal antibodies...
March 2024: Paediatric Drugs
https://read.qxmd.com/read/37873859/subtractive-immunization-as-a-method-to-develop-respiratory-syncytial-virus-rsv-specific-monoclonal-antibodies
#3
JOURNAL ARTICLE
Lotte Jacobs, Kim Stobbelaar, Annick Heykers, Paul Cos, Peter Delputte
Respiratory Syncytial Virus (RSV) is a significant cause of lower respiratory tract infections in the young, the elderly, and in immunodeficient patients. As such, the virus represents an important cause of morbidity and mortality worldwide. Development of monoclonal antibodies against RSV has resulted in a commercial prophylaxis, palivizumab (Synagis® ), and different antibodies that have improved our understanding of the structure of the viral proteins. In this study, a different immunization technique, subtractive immunization, was evaluated for its applicability to develop RSV-specific antibodies...
September 26, 2023: Antibodies
https://read.qxmd.com/read/37755690/two-vaccines-arexvy-and-abrysvo-for-prevention-of-rsv-disease
#4
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
October 2, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37682698/nirsevimab-beyfortus-for-prevention-of-severe-rsv-disease-in-young-children
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 18, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36452169/identification-of-risk-factors-in-pre-term-infants-with-abnormal-general-movements
#6
JOURNAL ARTICLE
Małgorzata Domagalska-Szopa, Andrzej Szopa, María Eugenia Serrano-Gómez, Magdalena Hagner-Derengowska, Jakub Behrendt
INTRODUCTION: This study aimed to investigate the relationship between prenatal, perinatal, and postnatal risk factors for neurodevelopmental impairment (NDI) with the outcomes of General Movement (GM) Assessment (GMA) in pre-term infants at 3-5 months of age. We sought to identify the risk factors associated with the predictors of psychomotor development in pre-term newborns, such as normal fidgety movements (FMs), absent FMs, or abnormal FMs, assessed during the fidgety period of motor development...
2022: Frontiers in Neurology
https://read.qxmd.com/read/35572846/post-translational-modifications-and-glycoprofiling-of-palivizumab-by-uhplc-rplc-hilic-and-mass-spectrometry
#7
JOURNAL ARTICLE
Kulwinder Singh Sran, Yogita Sharma, Tejinder Kaur, Alka Rao
UNLABELLED: Viral infections are progressively becoming a global health burden, as witnessed in the ongoing COVID-19 pandemic. Respiratory Syncytial Virus (RSV) is another highly contagious negative-sense RNA virus that causes lower respiratory tract infections and high mortality in infants. Palivizumab (Synagis® ) is the only humanized monoclonal antibody (mAb) approved by the FDA against RSV. The virus neutralization efficacy often depends on the nature and abundance of the glycoforms in therapeutic mAbs...
2022: Journal of proteins and proteomics
https://read.qxmd.com/read/35408661/protein-and-peptide-substances-in-the-treatment-of-respiratory-syncytial-infection-current-state
#8
REVIEW
Anna A Shtro, Galina D Petukhova, Aleksandra S Romanova
Respiratory syncytial virus infection (RSVI) is an acute medical and social problem in many countries globally. Infection is most dangerous for infants under one year old and the elderly. Despite its epidemiological relevance, only two drugs are registered for clinical use against RSVI: ribavirin (approved in a limited number of countries due to side effects) and palivizumab (Synagis), which is intended only for the prevention, but not the treatment, of infection. Currently, various research groups are searching for new drugs against RSV, with three main areas of research: small molecules, polymeric drugs (proteins and peptides), and plant extracts...
March 31, 2022: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/34937485/breakthrough-therapy-designation-of-nirsevimab-for-the-prevention-of-lower-respiratory-tract-illness-caused-by-respiratory-syncytial-virus-infections-rsv
#9
REVIEW
Harrison C Bergeron, Ralph A Tripp
INTRODUCTION: Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract infection (LRTI) in infants and young children. Palivizumab is an RSV-specific prophylactic for use in high-risk infants but treatment requires monthly injections and only modestly reduces hospitalization. Thus, new immunoprophylactic candidates are under development. Nirsevimab (MEDI8897) is a monoclonal antibody with an extended half-life developed to protect infants for an entire RSV season with a single dose...
January 2022: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/34163482/hyper-enriched-anti-rsv-immunoglobulins-nasally-administered-a-promising-approach-for-respiratory-syncytial-virus-prophylaxis
#10
JOURNAL ARTICLE
Emilie Jacque, Claire Chottin, Daphné Laubreton, Michel Nogre, Cécile Ferret, Sandrine de Marcos, Linda Baptista, Carole Drajac, Philippe Mondon, Christophe De Romeuf, Marie-Anne Rameix-Welti, Jean-François Eléouët, Sami Chtourou, Sabine Riffault, Gérald Perret, Delphyne Descamps
Respiratory syncytial virus (RSV) is a public health concern that causes acute lower respiratory tract infection. So far, no vaccine candidate under development has reached the market and the only licensed product to prevent RSV infection in at-risk infants and young children is a monoclonal antibody (Synagis® ). Polyclonal human anti-RSV hyper-immune immunoglobulins (Igs) have also been used but were superseded by Synagis® owing to their low titer and large infused volume. Here we report a new drug class of immunoglobulins, derived from human non hyper-immune plasma that was generated by an innovative bioprocess, called Ig cracking, combining expertises in plasma-derived products and affinity chromatography...
2021: Frontiers in Immunology
https://read.qxmd.com/read/33107769/updated-cost-effectiveness-analysis-of-palivizumab-synagis-for-the-prophylaxis-of-respiratory-syncytial-virus-in-infant-populations-in-the-uk
#11
REVIEW
Omendra Narayan, Anthony Bentley, Katie Mowbray, Monika Hermansson, Dominic Pivonka, Eric Ngonga Kemadjou, Jonathan Belsey
AIMS: Respiratory syncytial virus (RSV) is a common cause of respiratory infection in infants and severe infection can result in hospitalization. The passive immunization, palivizumab, is used as prophylaxis against RSV, however, use in the UK is restricted to populations at high risk of hospitalization. This study assesses the cost-effectiveness (CE) of palivizumab in premature infants with and without risk factors for hospitalization (congenital heart disease [CHD], bronchopulmonary dysplasia [BPD])...
December 2020: Journal of Medical Economics
https://read.qxmd.com/read/32164518/monoclonal-antibodies-against-infectious-microbes-so-long-and-too-little
#12
REVIEW
Gerard M Raj, Rekha Priyadarshini, Sakthibalan Murugesan, Mangaiarkkarasi Adhimoolam
Monoclonal antibodies (mAbs) as alternatives or more often as complementary to the conventional antimicrobials have been developed for the management of infectious conditions for the past two decades. These pharmacotherapeutic strategies are inevitable as the burden of antimicrobial resistance is far-reaching in recent times. MAbs are part of the targeted pharmacotherapy armamentarium with a high degree of specificity - hence, exert comparatively superior efficacy and tolerability than the conventional polyclonal antisera...
2021: Infectious Disorders Drug Targets
https://read.qxmd.com/read/31397431/-prospects-for-the-use-of-peptides-against-respiratory-syncytial-virus
#13
JOURNAL ARTICLE
I P Shilovskiy, S M Andreev, K V Kozhikhova, A A Nikolskii, M R Khaitov
The human respiratory syncytial virus (RSV) is one of the most common viral pathogens that affects the lower respiratory tract and could be a reason of bronchiolitis and/or pneumonia. Currently, there are no available effective ways of treating the RSV infection. Attempts to develop preventive vaccine have been unsuccessful. The only therapeutic agent used for RSV treatment is virazole (ribavirin); however, it induces adverse effects. Medications based on neutralizing monoclonal antibodies, such as IGIV (Respigam), palivizumab (Synagis), and MEDI-524 (Numab), are under clinical trials; however, their use will be limited by their high cost...
July 2019: Molekuliarnaia Biologiia
https://read.qxmd.com/read/30389195/respiratory-syncytial-virus-fusion-nanoparticle-vaccine-immune-responses-target-multiple-neutralizing-epitopes-that-contribute-to-protection-against-wild-type-and-palivizumab-resistant-mutant-virus-challenge
#14
JOURNAL ARTICLE
Brian E Gilbert, Nita Patel, Hanxin Lu, Ye Liu, Mimi Guebre-Xabier, Pedro A Piedra, Gregory Glenn, Larry Ellingsworth, Gale Smith
Human respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory tract infections in newborns, young children, elderly, and immune-compromised. The RSV fusion (F) glycoprotein is a major focus of vaccine development and the target of palivizumab (Synagis®) which is licensed as an immuno-prophylactic for use in newborn children at high risk of infection. However, clinical use of a narrowly targeted monoclonal antibodies leads to the generation of escape mutant strains that are fully resistant to neutralization by the antibody...
December 18, 2018: Vaccine
https://read.qxmd.com/read/30020201/risk-factors-and-main-indications-for-palivizumab-prophylaxis-in-a-second-season-population-results-from-the-german-synagis-registry-2009-2016
#15
MULTICENTER STUDY
Arne Simon, Susanne Gehrmann, Gudrun Wagenpfeil, Stefan Wagenpfeil
BACKGROUND: After national recommendations, palivizumab is administered in Germany to high-risk infants to prevent hospitalizations related to respiratory syncytial virus (RSV) infection. Limited data are available to characterize those children who receive palivizumab in 2 consecutive RSV seasons. METHODS: This was a comparative analysis of data from a postmarketing observational study (German SYNAGIS Registry, AbbVie Germany GmbH & Co.KG, Wiesbaden) detailing RSV-related risk factors and main indications for palivizumab in 920 children who received at ≥1 palivizumab injection in a second season between 2010 and 2016 [second season population (SSP)]...
October 2018: Pediatric Infectious Disease Journal
https://read.qxmd.com/read/29768937/cotton-rat-model-for-testing-vaccines-and-antivirals-against-respiratory-syncytial-virus
#16
JOURNAL ARTICLE
M S Boukhvalova, K C Yim, Jcg Blanco
Respiratory syncytial virus is the leading cause of pneumonia and bronchiolitis in infants and is a serious health risk for elderly and immunocompromised individuals. No vaccine has yet been approved to prevent respiratory syncytial virus infection and the only available treatment is immunoprophylaxis of severe respiratory syncytial virus disease in high-risk infants with Palivizumab (Synagis® ). The development of respiratory syncytial virus vaccine has been hampered by the phenomenon of enhanced respiratory syncytial virus disease observed during trials of a formalin-inactivated respiratory syncytial virus in 1960s...
January 2018: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/29660756/use-of-palivizumab-in-germany-report-from-the-german-synagis%C3%A2-registry-2009-2016
#17
JOURNAL ARTICLE
Arne Simon, Susanne Gehrmann, Gudrun Wagenpfeil, Stefan Wagenpfeil
BACKGROUND: Following national recommendations, palivizumab is administered in Germany to high-risk infants to prevent hospitalizations related to Respiratory Syncytial Virus infection. METHODS: In this post marketing observational study (German SYNAGIS™ Registry) data on risk factors and the clinical course of children, who received at least one palivizumab injection between 2009-2016 (01 September to June 30) were entered into an internet-based data entry system by the attending physicians after informed consent...
September 2018: Klinische Pädiatrie
https://read.qxmd.com/read/29651734/palivizumab-use-in-infants-with-down-syndrome-report-from-the-german-synagis%C3%A2-registry-2009-2016
#18
MULTICENTER STUDY
Arne Simon, Susanne Gehrmann, Gudrun Wagenpfeil, Stefan Wagenpfeil
Infants with Down syndrome (DS) face an increased risk of respiratory tract infections. Recent studies describe DS as independent risk factor for a complicated clinical course in infants with respiratory syncytial virus (RSV) infection. The prospective observational German Synagis™ Registry comprises data from 249 children below 25 months of age with DS and palivizumab prophylaxis 2009-2016 (1191 administrations; mean 4.8 per patient and season). The median gestational age and the birth weight in patients without and with DS were 31 versus 37 weeks (P < 0...
June 2018: European Journal of Pediatrics
https://read.qxmd.com/read/27926583/evaluation-of-the-financial-and-health-burden-of-infants-at-risk-for-respiratory-syncytial-virus
#19
JOURNAL ARTICLE
Stephanie McCallum Blake, David Tanaka, Lisa M Bendz, Suzanne Staebler, Debra Brandon
BACKGROUND: Respiratory syncytial virus (RSV) is the leading viral cause of death in infants younger than 1 year. In July 2014, the American Academy of Pediatrics (AAP) Committee on Infectious Diseases concluded that the "limited clinical benefit" for infants born at more than 29 weeks' gestation, together with the associated high cost of the immunoprophylaxis, no longer supported the routine use of palivizumab (Synagis). PURPOSE: To evaluate the impact of the newly adopted AAP palivizumab prophylaxis administration on health and subsequent hospital costs of infants born between 29 and less than 32 weeks' gestation...
August 2017: Advances in Neonatal Care: Official Journal of the National Association of Neonatal Nurses
https://read.qxmd.com/read/27663736/rational-design-of-a-kv1-3-channel-blocking-antibody-as-a-selective-immunosuppressant
#20
JOURNAL ARTICLE
Rongsheng E Wang, Ying Wang, Yuhan Zhang, Chase Gabrelow, Yong Zhang, Victor Chi, Qiangwei Fu, Xiaozhou Luo, Danling Wang, Sean Joseph, Kristen Johnson, Arnab K Chatterjee, Timothy M Wright, Vân T B Nguyen-Tran, John Teijaro, Argyrios N Theofilopoulos, Peter G Schultz, Feng Wang
A variable region fusion strategy was used to generate an immunosuppressive antibody based on a novel "stalk-knob" structural motif in the ultralong complementary-determining region (CDR) of a bovine antibody. The potent Kv1.3 channel inhibitory peptides Moka1-toxin and Vm24-toxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both β-sheet and coiled-coil linkers. Structure-activity relationship efforts led to generation of the fusion protein Syn-Vm24-CDR3L, which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomolar to picomolar EC50 values)...
October 11, 2016: Proceedings of the National Academy of Sciences of the United States of America
keyword
keyword
55972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.